A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

Auteurs

P. Pautier, N. Penel, I. Ray-Coquard, A. Italiano, E. Bompas, C. Delcambre, J.-O. Bay, F. Bertucci, J. Delaye, C. Chevreau, D. Cupissol, L. Bozec, J.-C. Eymard, E. Saada, N. Isambert, C. Guillemet, M. Rios, S. Piperno-Neumann, G. Chenuc, F. Duffaud